title: Efficacy and acceptability of lanreotide Autogel® 120 mg at different dose intervals in patients with acromegaly previously treated with octreotide LAR.
abstract: OBJECTIVE
  To assess the efficacy of different dosing intervals of lanreotide, Somatuline Autogel® (Lan-ATG) 120 mg in patients with acromegaly, previously treated with octreotide, long-acting release (Oct-LAR).
  
  
  METHODS
  Patients previously on Oct-LAR 10, 20, or 30 mg were switched to 6 repeated deep subcutaneous injections of Lan-ATG 120 mg at intervals of 56, 42, or 28 days, respectively. After the third injection, dose intervals were adjusted on the basis of insulin-like growth factor 1 (IGF-1) levels.
  
  
  RESULTS
  The ITT (Intention To Treat) population comprised 35 patients who received at least one dose of study medication and at least one post-baseline efficacy assessment. Overall, 62.9% (n=22) of patients had normalised IGF-1 levels with Lan-ATG at study end (one injection interval after the 6 (th) injection of Lan-ATG), which was similar to the proportion at baseline (60.0% [n=21]). QoL did not change from baseline to study end. Patient preference for Lan-ATG was highest in the 56-day dosing interval group: 71%, 54% and 41% of the patients in the 56, 42 and 28 day groups, respectively, expressed a preference for treatment with Lan-ATG (preference for Oct-LAR: 29%, 9% and 35%, respectively, while the remainder had no preference).
  
  
  CONCLUSIONS
  Lan-ATG 120 mg injected at intervals of 56, 42 and 28 days provided equivalent hormonal control and QoL to Oct-LAR 10, 20 and 30 mg injected every 28 days, respectively. The proportion of patients preferring Lan-ATG treatment was greater in the longer injection interval groups.
authors.affiliation: Medizinische Klinik Innenstadt, Ludwig-Maximilians University, Munich, Germany. jochen.schopohl@med.uni-muenchen.de
authors.forename: J
authors.initials: J
authors.lastname: Schopohl
authors.forename: C J
authors.initials: CJ
authors.lastname: Strasburger
authors.forename: D
authors.initials: D
authors.lastname: Caird
authors.forename: K
authors.initials: K
authors.lastname: Badenhoop
authors.forename: F
authors.initials: F
authors.lastname: Beuschlein
authors.forename: M
authors.initials: M
authors.lastname: Droste
authors.forename: U
authors.initials: U
authors.lastname: Plöckinger
authors.forename: S
authors.initials: S
authors.lastname: Petersenn
mesh_terms: D000172:Acromegaly / Q000097:blood / Q000188:drug therapy* / Q000523:psychology; D004305:Dose-Response Relationship, Drug; D005260:Female; D019382:Human Growth Hormone / Q000097:blood; D006801:Humans; D007334:Insulin-Like Growth Factor I / Q000032:analysis; D008297:Male; D008875:Middle Aged; D015282:Octreotide / Q000627:therapeutic use; D017060:Patient Satisfaction; D010456:Peptides, Cyclic / Q000008:administration & dosage*; D011788:Quality of Life; D013004:Somatostatin / Q000008:administration & dosage / Q000031:analogs & derivatives*; D011795:Surveys and Questionnaires
chemical_list: D010456:Peptides, Cyclic; C060347:lanreotide; D019382:Human Growth Hormone; D013004:Somatostatin; D007334:Insulin-Like Growth Factor I; D015282:Octreotide